Article
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Clinical pharmacology and therapeutics - 1 Oct 2004
Sugimoto Mitsushige, Furuta Takahisa, Shirai Naohito, Kajimura Masayoshi, Hishida Akira, Sakurai Masaharu, Ohashi Kyoichi, Ishizaki Takashi
Abstract excerpt
OBJECTIVE: For the treatment of gastroesophageal reflux disease, intragastric pH should be lower than 4.0 for no more than 4 hours a day (<16.7%). We aimed to develop optimal dosage regimens for rabeprazole to control nocturnal acidity in relation to cytochrome P450 (CYP) 2C19 genotypes. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
